3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care

3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care

BCACP Exam Anchor: Anticoagulation management spans a major portion of ambulatory clinical pharmacy practice. Exam candidates must master $\text{CHA}_2\text{DS}_2\text{-VASc}$ point scoring thresholds, precise DOAC renal and clinical dose-reduction rules (specifically the apixaban "2 of 3 ABC" rule and edoxaban upper CrCl cutoff), mandatory warfarin indications, evidence-based peri-procedural interruption schedules, and immediate reversal protocols for life-threatening hemorrhage.

Stroke & Bleeding Risk Stratification in Atrial Fibrillation

In patients with non-valvular atrial fibrillation (AF), antithrombotic selection is guided by calculating the $\text{CHA}_2\text{DS}_2\text{-VASc}$ stroke risk score and assessing modifiable bleeding risks via the HAS-BLED score.

The $\text{CHA}_2\text{DS}_2\text{-VASc}$ Scoring System

Guideline Decision Thresholds

• Score $\ge 2$ in Men or $\ge 3$ in Women (Class 1 Recommendation): Oral anticoagulation is strongly recommended. Direct oral anticoagulants (DOACs) are preferred over warfarin.
• Score of 1 in Men or 2 in Women (Class 2b Recommendation): Oral anticoagulation may be considered based on shared clinical decision-making.
• Score of 0 in Men or 1 in Women (Class 3 / No Benefit): Omit all antithrombotic therapy. Clinical Pearl: Aspirin monotherapy is not recommended for stroke prevention in AF because it provides negligible stroke reduction while carrying substantial bleeding risk.

Bleeding Risk Assessment: HAS-BLED Score

• Evaluates: Hypertension (SBP $>160$), Abnormal renal/liver function (1 pt each), Stroke history, Bleeding history/predisposition, Labile INRs, Elderly ($>65$), Drugs/Alcohol (antiplatelets, NSAIDs, alcohol excess; 1 pt each).
• Clinical Rule: A high HAS-BLED score ($\ge 3$) is not a reason to withhold oral anticoagulation. Instead, it alerts the clinician to identify and remediate modifiable bleeding risk factors (uncontrolled blood pressure, concurrent NSAID use, alcohol misuse, and labile INR).

Direct Oral Anticoagulants (DOACs): Dosing & Adjustments

DOACs represent the standard of care for non-valvular atrial fibrillation and venous thromboembolism (VTE: DVT and PE) due to fixed dosing, lack of routine INR monitoring, minimal food interactions, and significantly lower rates of life-threatening intracranial hemorrhage compared to warfarin.

Warfarin Pharmacotherapy & Mandatory Indications

Warfarin acts as an antagonist of vitamin K epoxide reductase complex 1 (VKORC1), inhibiting the $\gamma$-carboxylation of vitamin K-dependent clotting factors (II, VII, IX, X) and natural regulatory anticoagulant proteins C and S.

Mandatory Clinical Indications for Warfarin (DOACs Contraindicated!)

Major randomized trials have established that DOACs are either ineffective or hazardous in specific conditions where warfarin remains the mandatory gold standard:

1. Mechanical Prosthetic Heart Valves: The RE-ALIGN trial demonstrated that dabigatran caused excess thromboembolic events (valve thrombosis, stroke) and major bleeding compared to warfarin. DOACs are strictly contraindicated with all mechanical heart valves.
   • Mechanical Mitral Valve: Target INR 2.5 to 3.5.
   • Mechanical Aortic Valve: Target INR 2.0 to 3.0 (Target 2.5 to 3.5 if additional risk factors present: AF, prior thromboembolism, LV dysfunction, or older-generation caged-ball/tilting-disc valve).
   • Bioprosthetic Valves: Warfarin target INR 2.0 to 3.0 for the initial 3 to 6 months post-implantation, after which DOACs or aspirin may be used.
2. Moderate-to-Severe Rheumatic Mitral Stenosis: DOACs are not approved; warfarin is required with target INR 2.0 to 3.0.
3. Triple-Positive Antiphospholipid Syndrome (APS): The TRAPS trial demonstrated an excess of arterial thromboembolic events (stroke, MI) with rivaroxaban compared to warfarin in patients positive for all 3 antibodies (lupus anticoagulant, anticardiolipin, and anti-$\beta_2$-glycoprotein I). Warfarin with target INR 2.0 to 3.0 is mandatory.

Warfarin Initiation & Acute VTE Bridging Protocol

• The Protein C/S Depletion Paradox: Factor VII (half-life ~6 hours) and Protein C (half-life ~8 hours) decline rapidly upon starting warfarin, while Factor II (prothrombin, half-life ~60–72 hours) declines slowly. This creates a transient, paradoxical hypercoagulable state during the first 24 to 48 hours.
• VTE Bridging Rule: In acute VTE, warfarin must be overlapped with a therapeutic parenteral anticoagulant (enoxaparin 1 mg/kg SC q12h, dalteparin, or IV UFH) for a minimum of 5 full days AND until the INR is $\ge 2.0$ for at least 24 consecutive hours (two therapeutic INRs 24 hours apart).

Critical Drug & Dietary Interactions

• CYP2C9 Inhibitors (Dramatically Increase INR / Bleeding Risk): Amiodarone, Fluconazole, Metronidazole, and Trimethoprim-Sulfamethoxazole (Bactrim). When initiating amiodarone, metronidazole, or Bactrim in a patient on stable warfarin, empirically decrease the warfarin maintenance dose by 30% to 50% and monitor INR in 3 to 5 days.
• CYP2C9 / CYP3A4 Inducers (Decrease INR / Thrombosis Risk): Rifampin, carbamazepine, phenobarbital, phenytoin, St. John's wort.
• Dietary Vitamin K: Green leafy vegetables (spinach, kale, collard greens, broccoli). Patients must be counseled on consistent weekly intake rather than strict avoidance.

Peri-Procedural Anticoagulation Management

Managing anticoagulation before elective invasive procedures requires balancing thromboembolic risk during interruption against procedural bleeding risk.

Elective DOAC Interruption Schedule

                                Elective Surgical / Invasive Procedure
                                                  │
               ┌──────────────────────────────────┴──────────────────────────────────┐
               ▼                                                                     ▼
     Low Bleeding Risk Procedure                                         High Bleeding Risk Procedure
(Minor dental, skin excision, cataract)                            (Major surgery, spinal/epidural, cardiac)
               │                                                                     │
      Hold DOAC 24 Hours                                                    Assess Renal Function (CrCl)
      (1 Day Prior / 1-2 Doses)                                                      │
               │                                              ┌──────────────────────┴──────────────────────┐
               ▼                                              ▼                                             ▼
      Resume DOAC 24 Hours Post-Op                    CrCl ≥50 mL/min                               CrCl 30-49 mL/min
      (Once Hemostasis Secured)                               │                                             │
                                                     Hold Apixaban / Rivaroxaban /                 Hold Apixaban / Rivaroxaban
                                                     Edoxaban / Dabigatran:                        for 72 Hours;
                                                     48 Hours (2 Days Prior)                       Hold Dabigatran for 72-96 Hours
                                                              │                                             │
                                                              └──────────────────────┬──────────────────────┘
                                                                                     │
                                                                                     ▼
                                                                        *DO NOT BRIDGE WITH HEPARIN!*
                                                                                     │
                                                                                     ▼
                                                                        Resume Full-Dose DOAC at 48-72 Hours
                                                                        (Once Complete Hemostasis Established)

• The "No Bridging for DOACs" Rule: Routine bridging with therapeutic LMWH or UFH during DOAC interruption is strictly contraindicated. Because DOACs have rapid clearance and predictable offset, bridging provides zero thromboembolic benefit while tripling major peri-procedural bleeding rates.

Warfarin Interruption & Bridging Protocol

• Interruption: Discontinue warfarin 5 days prior to surgery to allow the INR to normalize to $<1.5$.
• Selective Bridging Indications (Therapeutic LMWH / Enoxaparin 1 mg/kg SC q12h):
  • High Thromboembolic Risk (Bridge!): Any mechanical mitral valve, mechanical aortic valve with additional risk factors, recent stroke/TIA within 3 months, or $\text{CHA}_2\text{DS}_2\text{-VASc} \ge 7\text{ to } 8$.
  • Low/Moderate Thromboembolic Risk (Do NOT Bridge!): Bileaflet mechanical aortic valve without risk factors, non-valvular AF with $\text{CHA}_2\text{DS}_2\text{-VASc} \le 6$, or VTE $>12$ months ago (the landmark BRIDGE trial proved bridging in these cohorts increases major bleeding with no reduction in stroke).
• Bridging Timing: Discontinue therapeutic SC LMWH 24 hours prior to surgery (IV UFH stopped 4 to 6 hours prior). Restart LMWH 24 hours post-op for minor surgery, or 48 to 72 hours post-op for high bleeding risk surgery.

Anticoagulation Reversal & Emergency Protocols